ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Eur Respir J 1988; 1:262-268
Copyright ©ERS Journals Ltd 1988

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bratel, T
Right arrow Articles by Ripe, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bratel, T
Right arrow Articles by Ripe, E

Original Articles

Cardiac function and central haemodynamics in severe chronic obstructive lung disease. Acute and long-term effects of felodipine

T Bratel, G Hedenstierna, H Lundquist, O Nyquist, and E Ripe

Eleven patients, with advanced chronic obstructive lung disease (COLD), received an infusion of the calcium antagonist felodipine at a rate of 0.9 mg/h. Pulmonary and systemic vascular resistances (PVR and SVR) at rest were reduced by 18% (p less than 0.05) and 33% (p less than 0.001), respectively. Cardiac output increased by 33%. The right ventricular and left ventricular ejection fractions (RVEF and LVEF), measured by equilibrium gated radionuclide ventriculography, increased by 32% (p less than 0.01) and 25% (p less than 0.01), respectively. During exercise both PVR and SVR fell by a mean of 30% (p less than 0.01). RVEF and LVEF both increased by about 14% (p less than 0.05 and p less than 0.01). After three months of oral felodipine treatment, a dose-related decrease in PVR was noted at rest (r = -0.83) compared with pretreatment values. There was an increase in RVEF which correlated to a reduction in PVR (r = -0.76). Three patients discontinued the trial due to side effects. It is concluded that the reduction of PVR induced by felodipine is accompanied by an improvement in right heart function as measured by ejection fraction measurements.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by the European Respiratory Society.